Radiofrequency ablation combined with transcatheter arterial chemoembolization for recurrent liver cancer

doi:10.4240/wjgs.v16.i6.1756

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1032)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

HTML

478

Figures (1-1)

139

Tables (1-4)

151

Sum=801

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

139

Sum=187

Jun 27, 2024 (publication date) through Jan 22, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

World J Gastrointest Surg. Jun 27, 2024; 16(6): 1756-1764
Published online Jun 27, 2024. doi: 10.4240/wjgs.v16.i6.1756

Table 3 Comparison of alpha-fetoprotein, alanine aminotransferase, and total bilirubin between two groups of patients (mean ± SD)

Index		TACE + RFA group (n = 45)	RFA group (n = 45)	t	P value
AFP (ng/L)	Before treatment	423.35 ± 25.64	422.47 ± 24.85	0.165	0.869
AFP (ng/L)	After treatment	86.21 ± 26.71^a	126.70 ± 38.21^a	5.826	< 0.001
ALT (U/L)	Before treatment	283.61 ± 21.63	279.82 ± 20.09	0.861	0.392
ALT (U/L)	After treatment	47.34 ± 5.22^a	109.23 ± 25.32^a	16.059	< 0.001
TBiL (μmol/L)	Before treatment	91.37 ± 8.58	91.64 ± 8.94	0.146	0.884
TBiL (μmol/L)	After treatment	36.26 ± 4.23^a	48.83 ± 4.54^a	13.589	< 0.001

^aP < 0.05, compared with before treatment.

TACE: Transcatheter arterial chemoembolization; RFA: Radiofrequency ablation; AFP: Alpha-fetoprotein; ALT: Alanine aminotransferase; TBiL: Total bilirubin.

Citation: Guo JY, Zhao LL, Cai HJ, Zeng H, Mei WD. Radiofrequency ablation combined with transcatheter arterial chemoembolization for recurrent liver cancer. World J Gastrointest Surg 2024; 16(6): 1756-1764
URL: https://www.wjgnet.com/1948-9366/full/v16/i6/1756.htm
DOI: https://dx.doi.org/10.4240/wjgs.v16.i6.1756